Torrent Pharma Q4 revenue pc, net profit rises 11 pc
Ahmedabad, 20 May (UNI) Torrent Pharmaceuticals Limited on Tuesday announced its financial results for the fourth quarter and full year ended 31 March 2025, reporting steady growth across key metrics.
For Q4 FY25, the company posted revenue of Rs 2,959 crore, marking an 8 percent year-on-year increase. Gross margin remained stable at 75.3 percent. Operating EBITDA rose 9 percent to Rs. 964 crore, while net profit after tax climbed 11 percent to Rs. 498 crore. Adjusted for exceptional items and inventory revaluation, operating EBITDA stood at Rs. 981 crore, an 11 percent rise.
For the full fiscal year, Torrent reported revenues of Rs 11,516 crore, up 7 percent from the previous year. Operating EBITDA grew 10 percent to Rs. 3,721 crore, with net profit reaching Rs 1,911 crore, reflecting a 15 percent increase after adjustments for exceptional items.
The company's India business continued its robust performance with Q4 revenues of Rs 1,545 crore, growing 12 percent and outperforming the Indian Pharmaceutical Market (IPM) growth of 8 percent. Torrent's chronic therapy segment expanded 14 percent compared to 9 percent IPM growth. The company holds 21 brands in the Top 500 IPM brands, including 14 brands with sales exceeding Rs 100 crore.
In Brazil, revenues declined 6 percent to Rs. 351 crore, primarily due to the depreciation of the Brazilian Real. However, constant currency revenues increased by 5 percent. Torrent's Brazil operations grew 13 percent compared to a 7 percent market growth. Germany revenues rose 2 percent to Rs. 286 crore, supported by new tender wins and cost efficiency initiatives. The US market recorded a 15 percent revenue growth in Q4 to Rs. 302 crore, with constant currency growth at 10 percent.
Torrent has declared an interim dividend of Rs. 26 per equity share (face value Rs. 5). The Board has recommended a final dividend of Rs. 6 per share, subject to shareholders' approval.
In a strategic leadership move, Torrent's Board approved the appointment of Aman Mehta as Managing Director, effective 1 August 2025, as part of its long-term succession planning.
Torrent Pharmaceuticals, the flagship entity of the Torrent Group, ranks seventh in the Indian pharmaceutical market and holds leadership positions in cardiovascular, gastrointestinal, central nervous system, and cosmo-dermatology segments.
The company operates in over 50 countries, runs eight manufacturing facilities including five USFDA-approved plants, and maintains a strong focus on R&D with over 750 scientists.
UNI BDN GNK
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
15 minutes ago
- Business Standard
NSE SME Nikita Papers crumples on debut
Shares of Nikita Papers were trading at Rs 85.50 on the NSE, a discount of 17.79% compared with the issue price of Rs 104. The scrip was listed at Rs 90, a discount of 13.46% compared with the initial public offer (IPO) price. The stock was currently frozen at its lower limit of 5% over its listing price. The counter hit a high of Rs 92 and a low of Rs 85.50. About 4.06 lakh shares of the company changed hands at the counter. Nikita Papers' IPO was subscribed 1.40 times. The issue opened for bidding on 27 May 2025 and it closed on 29 May 2025. The price band of the IPO was set at Rs 95 to Rs 104 per share. The IPO comprised fresh issue of 64,94,400 equity shares. The promoter and promoter group shareholding diluted to 59.219% from 80.38% pre-issue. The company intends to utilize the net proceeds to meet capital expenditure for setting up a power plant, working capital requirements, issue expenses, and general corporate purposes. Ahead of the Nikita Papers on 26 May 2025, raised Rs 9.03 crore from anchor investors. The board has allotted 8.68 lakh shares at Rs 104 per share to 4 anchor investors. Nikita Papers is a leading manufacturer of Kraft paper with an installed capacity of approximately 1,33,000 MTPA. The company produces Kraft paper ranging from 80 to 200 GSM in various Burst Factor (B.F.) grades, catering to diverse customer needs across the paper industry. As on 09 May 2025, the company had 208 employees. The company recorded revenue from operations of Rs 265.14 crore and net profit of Rs 15.68 crore for the period ended 31 December 2024.
Fashion Value Chain
18 minutes ago
- Fashion Value Chain
Swiss Military Opens First Exclusive Outlet in India
Global lifestyle brand Swiss Military has launched its first-ever Exclusive Brand Outlet (EBO) in Surat, Gujarat, marking a significant step in the brand's expansion across India. Known for delivering premium travel gear and lifestyle essentials in over 26 countries, Swiss Military's latest move underlines its growing focus on the Indian market. The Surat EBO showcases the full spectrum of the brand's products, including polycarbonate and polypropylene luggage, premium backpacks, business bags, and India's first kids' trolley range. The store boasts international-standard design, sleek aesthetics, and immersive merchandising, bringing a global retail experience to Indian consumers. 'With this launch, India becomes central to our growth vision,' said Anuj Sawhney, Managing Director. 'Surat is one of our highest-performing markets, making it the ideal launchpad for our exclusive store format.' Already present in over 4,000 retail touchpoints across India, Swiss Military's EBO format aims to deepen its connection with aspirational consumers who seek quality, innovation, and style. The store's opening day saw over 1,000 visitors, with exclusive promotions and immersive brand experiences. To explore the full collection, visit:
Mint
24 minutes ago
- Mint
Trump tariffs: Here's how Indian exporters of apparel, drugs and tyres are preparing for all contingencies
New Delhi/Mumbai: Indian exporters of apparel, automotive parts, pharmaceuticals and tyres – with significant shipments to the US – are preparing contingency plans or revising their business strategies to mitigate the business risk from the imposition of tariffs. US President Donald Trump's administration has imposed a 10% universal tariff on all imports from every country, including India. Gokaldas Exports Ltd, a listed garments exporter, will focus on expanding its business in Europe because tariffs have hurt business with its main export market – the US. 'Since there is a lot of tariff uncertainty, we are pivoting to Europe. The idea is not to reduce our US business in absolute terms, but for incremental business we will focus on Europe including the UK," said Sivaramakrishnan Ganapathi, managing director of Gokaldas Exports. Margins of apparel exporters including Gokaldas have come under pressure following the tariff levy. US retailers have been unable to pass on the increased cost to consumers and are pushing for their suppliers to share the burden, Ganapathi said. Also Read | As US court declares Trump's tariffs illegal, experts urge India to reassess trade talks 'In the short term, we may also have to bear some of that cost just to keep up the relationships," he said. Gokaldas got about three-fourths of its ₹3,864 crore FY25 revenue from the US. The US is the largest export destination for Indian apparel exports. This is because competing apparel-exporting nations Bangladesh, Vietnam, Sri Lanka and Pakistan get preferential tariff rates in Europe, putting Indian exporters at a disadvantage. India's in-principle trade agreement with the UK last month and progressing talks with the European Union could now level the playing field for Indian exporters. 'Once an FTA with the UK is finalised, it will bring at least a $1 billion apparel export opportunity for India. The opportunity in the EU will be much larger. We should ready ourselves up for this incremental business," Ganapathi said. India exported readymade garments worth $16 billion ( ₹1.35 trillion) in FY25, as per data from the Apparel Export Promotion Council, an industry group. India business Indian tyre companies are chalking out similar contingency plans. The US is a key export market for Indian tyremakers, constituting about one-fifth of the country's total overseas tyre sales of $3 billion in FY24. Balkrishna Industries Ltd, which gets almost three-fourths of its revenue from exports, will focus on expanding business in India with a series of product launches. The company now targets 8% of the global tyre market by 2030 compared with its earlier goal of a 10% share. "Please note that we are under a slow-moving economy. There are wars happening, there are trade wars happening. Uncertain times are there. So that is why we are looking at it very conservatively," Rajiv Poddar, managing director at Balkrishna Industries, said on an earnings call on 24 May. 'In case anything changes and there's a catalyst, we are absolutely ready to pounce on that opportunity and go back to our original vision of 10%." Also Read | India's exports face geopolitical woes but trade deals offer relief: RBI report Ceat, which acquired Canada's Camso in December, is betting that India will be successful in signing a bilateral trade pact with the US before Sri Lanka and is planning to change its tyre distribution accordingly. Camso gets 30% of its business from the US through its two manufacturing facilities in Sri Lanka. "In case the tariffs go through, we will produce for the United States from Indian facilities if tariffs are lower here and for Europe from Sri Lanka," said Arnab Banerjee, managing director and CEO at Ceat. Apprehensive pharma Indian pharmaceutical companies are exploring partnerships and investment opportunities to manufacture in the US. While the pharmaceuticals sector has not been slapped with tariffs yet by the US, Indian exporters are apprehensive of surprise levies by Trump. 'We have a very good balance sheet; we have a very healthy financial capacity. We are always looking for opportunities," Dr. Reddy's Laboratories chief executive Erez Israeli said last month on investing in the US. 'We are not rushing, and we are not obliged for any commitment… But we certainly want to be in the United States long term. We will look for the relevant opportunity for us." Also Read | Bitter pill for Indian pharma as Trump tariffs could hurt exports by $2.25 billion The contingency plans of pigment manufacturer Sudarshan Chemicals include leveraging its ₹1,180 crore acquisition of Germany's Heubach Group. Heubach has a plant in the US as well as 19 units in Europe, allowing it the flexibility to tweak its distribution depending on the tariff scenario. "The new acquisition gives us a lot of flexibility. If there are tariffs on India, we supply from Europe into the US market," Rajesh Rathi, managing director of Sudarshan Chemicals, told Mint in March. Jessica Jani in Mumbai contributed to this story.
